QuantumBio Inc. Awarded Department of Defense Grant to Develop Tools That Will Counter Biothreats: Funding Will Facilitate Adaptation of Technology Originally Designed for Drug Discovery
July 05, 2005 Filed in: News
State College, PA – July 5, 2005. QuantumBio
Inc., headquartered in Harrisburg, PA with offices in
State College, PA and San Diego, CA, has been
selected to receive a Phase I Small Business
Innovation Research (SBIR) grant, valued at $63,353,
from the U.S. Army Research Office. Titled “In
Silico Screening for Biothreat
Countermeasures”, the project – under the
direction of Principle Investigator Lance Westerhoff
− will apply QuantumBio’s novel quantum
mechanics-based technology to the study of
next-generation tools to counter bioterrorism.
Originally developed for the pharmaceutical industry, the company’s in silico (computer aided) drug discovery tools are ideally suited to counter-bioterrorism efforts, where, in the case of a bioterrorist attack, the Department of Defense will require fast and accurate prediction methods to quickly determine viable treatment options.
At a fundamental level, these technologies address many of the same needs as those of the drug discovery industry. QMScore – QuantumBio’s propriety scoring algorithm – along with its various support products − uses the power and precision of quantum mechanics to solve the problems of the defense and pharmaceutical industries alike. In the proposed research, to be conducted in collaboration with a number of industry partners, further validation will be performed on QMScore.
At the conclusion of this research phase, QuantumBio will further expand on the development of a user-friendly application for drug discovery and counter-bioterrorism through the stronger integration of QMScore and QuantumBio’s molecular modeling platform, CHEMIX, with a knowledge management and intelligent workflow platform. At the same time, further research into the various applications of this novel technology will be performed. The ultimate goal of this project is the development of an intelligent and adaptive molecular modeling system for quantum mechanics-based drug discovery and counter-bioterrorism.
About QuantumBio
QuantumBio, Inc is accelerating drug discovery efforts by providing pharmaceutical, biotechnology companies and life science research organizations with a next generation of Computer-Assisted Drug Design (CADD) and Computer-Assisted Molecular Modeling (CAMM) solutions based on the increased accuracy and power of quantum mechanics. These solutions include a number of options tailored to each customer’s specific requirements including software licensing, services, and customization. Additional information is available at http://www.quantumbioinc.com or by email sales@quantumbioinc.com or by calling 814-235-6908.
Note: The project or effort depicted is sponsored by the U.S. Army Research Office, and that the content of the this press release does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred.
Originally developed for the pharmaceutical industry, the company’s in silico (computer aided) drug discovery tools are ideally suited to counter-bioterrorism efforts, where, in the case of a bioterrorist attack, the Department of Defense will require fast and accurate prediction methods to quickly determine viable treatment options.
At a fundamental level, these technologies address many of the same needs as those of the drug discovery industry. QMScore – QuantumBio’s propriety scoring algorithm – along with its various support products − uses the power and precision of quantum mechanics to solve the problems of the defense and pharmaceutical industries alike. In the proposed research, to be conducted in collaboration with a number of industry partners, further validation will be performed on QMScore.
At the conclusion of this research phase, QuantumBio will further expand on the development of a user-friendly application for drug discovery and counter-bioterrorism through the stronger integration of QMScore and QuantumBio’s molecular modeling platform, CHEMIX, with a knowledge management and intelligent workflow platform. At the same time, further research into the various applications of this novel technology will be performed. The ultimate goal of this project is the development of an intelligent and adaptive molecular modeling system for quantum mechanics-based drug discovery and counter-bioterrorism.
About QuantumBio
QuantumBio, Inc is accelerating drug discovery efforts by providing pharmaceutical, biotechnology companies and life science research organizations with a next generation of Computer-Assisted Drug Design (CADD) and Computer-Assisted Molecular Modeling (CAMM) solutions based on the increased accuracy and power of quantum mechanics. These solutions include a number of options tailored to each customer’s specific requirements including software licensing, services, and customization. Additional information is available at http://www.quantumbioinc.com or by email sales@quantumbioinc.com or by calling 814-235-6908.
Note: The project or effort depicted is sponsored by the U.S. Army Research Office, and that the content of the this press release does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred.